Original Research Article| Volume 120, 109788, April 2023

Download started.


A randomized double blinded clinical trial to explore the clinical outcomes of vaginal isonicotinic acid hydrazide (INH) administration six hours prior to T380A intrauterine device insertion in persons delivered only by cesarean delivery



      To compare insertion pain and ease of insertion in participants with a prior caesarean delivery having copper intrauterine device (IUD) after pretreatment with isonicotinic acid hydrazide (INH) 900 mg vaginally or placebo.

      Study design

      From September 2020 to September 2021, we conducted a randomized, double-blind, placebo-controlled experiment at Aswan University Hospital in Egypt with participants who were delivered solely by caesarean delivery and desired copper T380A IUD insertion. The participants were randomly assigned to either vaginal INH or placebo six hours before IUD insertion in a 1:1 ratio. The primary objective of the research was the individuals' self-reported pain during cervical tenaculum placement, sound insertion, IUD insertion, and 5 minutes after the placement, as measured by a 10-cm visual analogue scale (VAS). Our secondary outcomes were ease of insertion, satisfaction, the need for analgesics, and adverse effects. IUD insertion ease was graded from 0 to 10 on a 10-cm VAS scale, with 0 suggesting very easy insertion and 10 denoting extremely difficult insertion.


      When compared to the placebo group, the INH group experienced considerably less pain during IUD insertion ( 2.9 ± 0.85 v s . 5.11 ± 0.82 ; p < 0.01 ) , lower median ease of insertion score ( 3 ( 1 4 ) v s . 5 ( 3 6 ) ; p < 0.01 ) , and better satisfaction ( 8.17 ± 0.69 v s . 5.57 ± 0.75 ) . The two groups had comparable side effects.


      Vaginal INH administered before IUD insertion reduce the amount of discomfort participants feel throughout the process in individuals who had previously only been delivered via CD. It also has the potential to make insertion easier.


      In participants who were delivered solely by CD before, vaginal INH given prior to IUD placement reduces the amount of discomfort participants experience throughout the procedure. Furthermore, it could increase the ease of insertion.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lotke PS.
        Increasing use of long-acting reversible contraception to decrease unplanned pregnancy.
        Obstetr Gynecol Clin. 2015; 42: 557-567
        • McClellan K
        • Temples H
        • Miller L.
        The latest in teen pregnancy prevention: long-acting reversible contraception.
        J Pediatr Health Care. 2018; 32: e91-e97
        • Gemzell-Danielsson K
        • Jensen JT
        • Monteiro I
        • Peers T
        • Rodriguez M
        • Di Spiezio Sardo A
        • Bahamondes L.
        Interventions for the prevention of pain associated with the placement of intrauterine contraceptives: an updated review.
        Acta Obstet Gynecol Scand. 2019; 98: 1500-1513
        • Lopez LM
        • Bernholc A
        • Hubacher D
        • Stuart G
        • Van Vliet HA
        Immediate postpartum insertion of intrauterine device for contraception.
        Cochrane Database Syst Rev. 2015;
        • Abdellah MS
        • Abbas AM
        • Hegazy AM
        • El-Nashar IM.
        Vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective cesarean section: a randomized double-blind clinical trial.
        Contraception. 2017; 95: 538-543
        • Zapata LB
        • Jatlaoui TC
        • Marchbanks PA
        • Curtis KM.
        Medications to ease intrauterine device insertion: a systematic review.
        Contraception. 2016; 94: 739-759
        • Esposito CP
        • LoGiudice J.
        Beliefs and Use of Intrauterine Devices (IUDs) among women's health care providers.
        J Nurse Practitioners. 2019; 15: 682-687
        • Thomson AJ
        • Lunan CB
        • Cameron AD
        • Cameron IT
        • Greer IA
        • Norman JE.
        Nitric oxide donors induce ripening of the human uterine cervix: a randomised controlled trial.
        BJOG. 1997; 104: 1054-1057
        • Haghighi L
        • Mohabatian B.
        Isonicotinic acid hydrazide (INH): a new agent for cervical ripening at term.
        J Obstet Gynaecol. 2015; 35: 251-254
        • Yilmaz HR
        • Uz E
        • Gökalp O
        • Özçelik N
        • Çiçek EK
        • Özer MK.
        Protective role of caffeic acid phenethyl ester and erdosteine on activities of purine-catabolizing enzymes and level of nitric oxide in red blood cells of isoniazid-administered rats.
        Toxicol Ind Health. 2008; 24: 519-524
        • Haghighi L
        • Najmi Z
        • Rokhgireh S
        • Moradi Y.
        Intravaginal isonicotinic acid hydrazide (INH) versus misoprostol for cervical ripening prior to hysteroscopy.
        Obstetr Gynecol Sci. 2020; 63: 514-520
        • World Health Organization
        World Health Organization. Reproductive Health. Medical eligibility criteria for contraceptive use.
        World Health Organization, 2010
      1. Insertion technique for the Copper T380A IUD | RHL n.d. 316 317 (accessed October 8, 2019).

        • Rowbotham M.C.
        What is a “clinically meaningful” reduction in pain?.
        Pain. 2001; 94: 131-132
        • Jensen M.P.
        • Chen C.
        • Brugger A.M.
        Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain.
        J Pain. 2003; 4: 407-414
        • Allen R.H.
        • Raker C.
        • Goyal V.
        Higher dose cervical 2% lidocaine gel for IUD insertion: a randomized controlled trial.
        Contraception. 2013; 88: 730-736
        • Facchinetti F
        • Piccinini F
        • Volpe A.
        Chemical ripening of the cervix with intracervical application of sodium nitroprusside: a randomized controlled trial.
        Hum Reprod. 2000; 15: 2224-2227
        • Arteaga-Troncoso G
        • Villegas-Alvarado A
        • Belmont-Gomez A
        • Martinez-Herrera FJ
        • Villagrana-Zesati R
        • Guerra-Infante F.
        Intracervical application of the nitric oxide donor isosorbide dinitrate for induction of cervical ripening: a randomised controlled trial to determine clinical efficacy and safety prior to first trimester surgical evacuation of retained products of conception.
        BJOG. 2005; 112 (Dec): 1615-1619
        • Chan CC
        • Tang OS
        • Ng EH
        • Li CF
        • Ho PC.
        Intracervical sodium nitroprusside versus vaginal misoprostol in first trimester surgical termination of pregnancy: a randomized double-blinded controlled trial.
        Hum Reprod. 2005; 20: 829-833
        • Todd KH
        • Funk KG
        • Funk JP
        • Bonacci R.
        Clinical significance of reported changes in pain severity.
        Ann Emerg Med. 1996; 27: 485-489
        • Gallagher EJ
        • Liebman M
        • Bijur PE.
        Prospective validation of clinically important changes in pain severity measured on a visual analog scale.
        Ann Emerg Med. 2001; 38: 633-638
        • Bednarek P
        • Micks E
        • Jensen J.
        The effect of nitroprusside on the IUD insertion experience in nulligravid women: a pilot study.
        Contraception. 2012; 86: 320
        • Micks EA
        • Jensen JT
        • Bednarek PH.
        The effect of nitroglycerin on the IUD insertion experience in nulliparous women: a pilot study.
        Contraception. 2014; 90: 60-65

      Linked Article